Definition
Neonatal jaundice occurs when the concentration of bilirubin in serum (TSB) increases to the point where the accumulation of bilirubin in skin becomes visible to the unaided eye in daylight conditions (or similar-quality artificial light). Such visual detection is possible when the TSB exceeds 5 to 6 mg/dL (85 to 100 mcmol/L) and varies between observers and lighting conditions. A distinction often is made between physiologic and nonphysiologic jaundice. This distinction is useful didactically but often not possible clinically. For simplicity, physiologic jaundice may be said to be present when bilirubin production is increased and excretion capacity is low as part of a normal transitional process. Nonphysiologic jaundice may be said to be present when bilirubin production is exaggerated beyond normal or bilirubin excretion is reduced below normal for the newborn period. The Table  summarizes some key concepts of neonatal bilirubin metabolism.
Bilirubin Metabolism Production
The life span of red cells in the newborn is about 1.5 to 3 months.
(1) Degradation of heme from red cells, myoglobin from muscle, and enzymes such as cytochromes and catalases leads to production of bilirubin. (2) Biliverdin is formed as an intermediate step. Carbon monoxide is a byproduct of this process and can be measured in exhaled breath, providing an estimate of bilirubin production. (3) Bilirubin production in the neonate has been estimated to be about 8.5 mg/kg per day, approximately double the rate of 4 mg/kg per day in adults. (4) The first step in heme catabolism ( Figure) involves heme oxygenase, an enzyme that is found in the reticuloendothelial system but also in other tissues. (6)(7) Reduction of biliverdin IX-alpha to bilirubin IX-alpha takes place in the cytosol, catalyzed by biliverdin reductase. (8) Bilirubin IX-alpha in the serum of humans occurs almost exclusively as the (4Z,15Z) isomer. The apparent lipophilic nature of this bilirubin isomer can be explained by the intramolecular hydrogen bonds between the side groups (Zϭzusammen -German for "together"). 
Transport and Protein Binding
Unconjugated bilirubin is transported in plasma bound to albumin, with a high binding affinity at the primary binding site. In addition, a secondary binding site has a lower affinity. Because bilirubin is tightly bound to albumin, concentrations of free ("unbound") bilirubin are in the low nanomolar range, even in babies who exhibit significant jaundice. (11) If the molar concentration of bilirubin exceeds that of albumin, the primary binding site is saturated, and free bilirubin concentrations increase. (12) The binding of bilirubin to albumin increases with postnatal age (13) but is reduced in sick infants (14) and in the presence of exogenous or endogenous binding competitors such as certain drugs. (15) Bilirubin also can bind to other proteins (eg, alphafetoprotein and ligandin), lipoproteins, and erythrocytes.
Uptake, Conjugation, and Excretion
When the bilirubin-albumin complex comes into contact with hepatocytes, bilirubin is transported into the cell. This process may be carrier-mediated. Excretion of conjugated bilirubin into bile occurs against a concentration gradient, making it a process that requires energy. Clearance of bilirubin from the hepatocyte is a saturable process, and after the first postnatal week appears to be the rate-limiting step in bilirubin excretion. The excretory transport maximum can be increased by drugs that stimulate bile flow, such as barbiturates. (20) Glucuronyl transferase activity increases 100-fold after birth, reaching adult values by 1 to 2 months of age. (23) In the first days after birth, conjugated bilirubin constitutes less than 2% of total bile pigment in serum. (24) Diconjugates make up about 20% of the total conjugated fraction in babies, less than half of the estimated 50%ϩ in adults. (24) Glucuronyl transferase is inducible. Thus, administering phenobarbital to pregnant women increases conjugation in the neonate. (25) Phenobarbital has been used both before and after birth to prevent or treat neonatal jaundice. (26) Dexamethasone and clofibrate also increase bilirubin conjugation.
Heme can be excreted directly in bile, but this is accompanied by the loss of iron. Heme oxygenase can be inhibited through the use of metal meso-and protoporphyrins, (27) and this is a therapy for neonatal jaundice that is undergoing testing. (28) Biliverdin also can be excreted in bile. The biologic puzzle of why humans do not excrete nontoxic biliverdin but process this one step further to potentially toxic bilirubin may have a partial answer in the discovery that bilirubin is a free radical quencher. (29) Also, bilirubin can diffuse through the placental membranes from fetus to mother, whereas biliverdin would have needed a transporter.
Alternate pathways for bilirubin disposition through the liver also may exist. Thus, there is evidence that hemin, biliverdin, and bilirubin can induce such pathways by activating the aryl hydrocarbon receptor that, in turn, activates hepatic CYP1A1 gene expression. (30) Whether such pathways play any role in human infants currently is not known.
When bilirubin enters the bowel, deconjugation may occur in the small intestine, mediated by betaglucuronidases in the brush border. Unconjugated bilirubin then can be reabsorbed into the circulation. This cycle of conjugation, excretion, deconjugation, and reabsorption is called enterohepatic circulation. Enterohepatic circulation may be significant in the newborn, in part due to limited nutrient intake in the first postnatal days, which prolongs intestinal transit time. However, it also is believed that factors in human milk in some mother-infant dyads, which have not been unequivocally identified, may contribute to increased enterohepatic circulation in so-called human milk-associated jaundice.
creasing from about 25 mcmol/L (1.5 g/dL) at 20 weeks of gestation to 30 mcmol/L (1.8 g/dL) at term. (26) Bilirubin metabolism is different in the fetus compared with the neonate. Unconjugated bilirubin in the fetus can be disposed of either by crossing the placenta into the maternal circulation or by passing through the fetal liver and being excreted into fetal bile. Conjugation and excretion into bile is associated with accumulation of a quantity of bilirubin in meconium corresponding to 5 to 10 times daily production. (19) However, most fetal bilirubin production must be handled differently.
Placental membranes are essentially impermeable to polar compounds such as biliverdin and bilirubin conjugates, but nonpolar compounds such as unconjugated bilirubin can diffuse across the membranes. A study in rhesus monkeys, which have a placenta structurally very similar to that in humans, found that more than 50% of bilirubin infused into the fetus was transferred intact across the placenta and excreted in maternal bile, with only 3% to 6% found in fetal bile. 
Bilirubin in Fetal Hemolytic Disease
When hemolysis occurs in the fetus in maternal alloimmunization, the concentration of TSB may increase from approximately 1.5 mg/dL (25 mcmol/L) at 20 weeks of gestation to approximately 4.1 mg/dL (70 mcmol/L) at 32 weeks' gestation. In a study of fetuses that developed anemia (hematocrit Ͻ30% [0.30]), 82% had serum bilirubin concentrations that exceeded the 97.5th percentile. (35) The increase in serum bilirubin was detectable weeks before anemia developed. Thus, although bilirubin can pass the placenta, hemolytic disease in the fetus causes some hyperbilirubinemia. Some of the bilirubin is conjugated and cannot cross the placenta, but the major fraction is unconjugated. (36) Therefore, it follows that the placenta has a limited capacity for transfer of bilirubin and that this capacity is exceeded in fetal hemolytic disease.
Bilirubin in the Amniotic Fluid
Although bilirubin has been found in amniotic fluid in early gestation, normally there is no bilirubin in amniotic fluid near term. Bilirubin initially was found in the amniotic fluid in cases of Rhesus immunization, (37) and the concentrations of bilirubin in amniotic fluid have been shown to correlate with the degree of fetal effects. Because amniotic fluid is primarily a product from the fetus, bilirubin in amniotic fluid probably comes from the fetus itself.
Mechanisms of Physiologic and Nonphysiologic Jaundice
Most newborns develop a serum unconjugated bilirubin value greater than 1.8 mg/dL (30 mcmol/L) during the first postnatal week. The incidence of significant neonatal jaundice varies among populations and geographic locations. For example, neonatal jaundice is more prevalent in populations living at high altitudes, likely due to increased red cell mass. Noninvasive bilirubin measurements on 490 term and near-term infants from a racially diverse background showed that 80% had bilirubin concentrations greater than 5 mg/dL (85 mcmol/L), (38) approximately the value at which the human eye can detect jaundice in the skin. The course of hyperbilirubinemia in neonates is characterized by a peak between the second and fourth postnatal days, followed by a decline that initially is rapid and subsequently tapers. Jaundice is a very common phenomenon in neonates and a frequent reason for clinical concern and investigation.
The term physiologic jaundice should be applied to jaundice in newborns due to the normal occurrences of increased breakdown of red cells in the presence of a low capacity for uptake, conjugation, and excretion of bilirubin in the liver. However, the distinction between physiologic and nonphysiologic jaundice in newborns often is not clear. Thus, the normally occurring mechanisms that produce hyperbilirubinemia may be exaggerated by both endogenous and exogenous factors.
Increased Heme Catabolism
The fetus lives in an oxygen-poor environment. To compensate for this, the fetus has a hemoglobin that is structurally different from the one formed in postnatal life as well as a higher hemoglobin concentration. These compensatory mechanisms are not needed after birth. Breakdown of fetal red cells, resulting in production of bilirubin, may be increased in congenital hemolytic anemias, in immunologic conditions such as maternal-fetal blood group incompatibilities, and due to drugs or toxins. Infections or bruising/hematomas also can shorten red cell survival. deficiency of ligandin beyond the physiologic degree is implicated in nonphysiologic jaundice. However, deficiency of UDPGT occurs in several hereditary disorders.
Increased Enterohepatic Circulation
Enterohepatic circulation occurs in the presence of delayed or interrupted passage of intestinal contents. This can happen in intestinal atresias, in infants in whom oral feedings are held for reasons of severe illness, and in infants receiving inadequate nutrition due to difficulties in establishing lactation ("lack-of-breast-milk jaundice"). It is also possible that increased enterohepatic circulation is involved in so-called human milk jaundice. 
Genetics and Bilirubin Metabolism
It is increasingly recognized that the risk for neonatal jaundice may be modulated by genetics. Crigler-Najjar syndrome and Arias syndrome are well-recognized causes of extreme jaundice in neonates. The impact of Gilbert syndrome on jaundice in the newborn also has become apparent. Crigler-Najjar syndrome is caused by a stop or nonsense mutation in the gene for UDP-GT1A1, Arias syndrome is due to a missense mutation in the same gene, and Gilbert syndrome is caused by mutations in the promoter sequence. (40) Recently, genetic polymorphism for the organic anion transporter protein OATP-2 was shown to be associated with a threefold increased risk for developing marked neonatal jaundice. (41) Glucose-6-phosphate dehydrogenase deficiency and other hereditary hemolytic anemias also are associated with increased risk of neonatal jaundice. In a recent study across three genes that had an impact on bilirubin metabolism (G6PD, UGT1A1, and OATP1B1), coexpression of two or more of these genes was common. (42) Accordingly, genetic polymorphisms probably are important in explaining some of the clinically observed variability in the course and degree of neonatal jaundice.
The Impact of Bilirubin Isomers
Isomers of bilirubin differ in their polarity. The predominant IX-alpha (Z,Z) isomer is almost insoluble in water, but the isomers that arise when bilirubin is exposed to light, primarily IX-alpha (Z,E) and lumirubin, are more polar and more soluble in water. (43) These watersoluble isomers can be excreted in bile and urine without conjugation, accounting for the therapeutic effect of phototherapy. By virtue of its lipophilic nature, bilirubin IX-alpha (Z,Z) can enter the brain. However, the presence of P-glycoprotein in the blood-brain barrier appears to block bilirubin entry to some extent, (44) so the concentration of bilirubin in brain is less than might be expected, given its solubility characteristics. It has been speculated that the more polar bilirubin photoisomers should be less able to diffuse across the blood-brain barrier. However, no experimental evidence to date supports this theoretically based hypothesis.
Conclusion
Bilirubin metabolism undergoes significant changes during fetal and neonatal life in terms of the balance of isomers, the processes involved in uptake into the hepatocyte, binding and conjugation inside the hepatocyte, and excretion into the bile. Several steps in the process that causes neonatal jaundice can be modulated both by endogenous and exogenous compounds. Drugs that increase the concentration of ligandin or the activity of bilirubin UDPGT are well documented but appear not to be used widely. Drugs that limit bilirubin production by inhibiting heme oxygenase are undergoing trials, but their eventual place in the routine management of neonatal jaundice remains to be determined. Enterohepatic circulation contributes to neonatal jaundice and is amenable to therapeutic intervention by formula feedings or other bilirubin binding or degrading agents.
